Endocyte (ECYT) Showing Signs Of Perilous Reversal Today

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified Endocyte ( ECYT) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Endocyte as such a stock due to the following factors:

  • ECYT has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $19.1 million.
  • ECYT has traded 102,906 shares today.
  • ECYT is down 3.1% today.
  • ECYT was up 13.1% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in ECYT with the Ticky from Trade-Ideas. See the FREE profile for ECYT NOW at Trade-Ideas

More details on ECYT:

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. ECYT has a PE ratio of 22.2. Currently there are 4 analysts that rate Endocyte a buy, no analysts rate it a sell, and 3 rate it a hold.

The average volume for Endocyte has been 1.1 million shares per day over the past 30 days. Endocyte has a market cap of $285.5 million and is part of the health care sector and drugs industry. The stock has a beta of 0.78 and a short float of 19.6% with 2.96 days to cover. Shares are down 24.7% year-to-date as of the close of trading on Tuesday.

If you liked this article you might like

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

A Small Biotech Sells for Less Than Cash

A Small Biotech Sells for Less Than Cash

A Small, but Promising Biotech Stock

A Small, but Promising Biotech Stock

4 Biotech Stocks Under $10 to Trade for Breakouts

Why Endocyte (ECYT) Stock Is Declining Today